Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET/CT

Mads Tranberg Christensen; Mads Ryø Jochumsen; Søren Klingenberg; Karina Dalsgaard Sørensen; Michael Borre; Kirsten Bouchelouche

doi:10.3390/diagnostics12010195

Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by ⁶⁸Ga-PSMA PET/CT

Mads Tranberg Christensen^*, Mads Ryø Jochumsen, Søren Klingenberg, Karina Dalsgaard Sørensen, Michael Borre, Kirsten Bouchelouche

^*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

10 Citations (Scopus)

Abstract

Objectives: To explore the existence of new predictors of the ⁶⁸Ga-Prostate-Specific Membrane Antigen (PSMA) PET/CT detection rate at biochemical recurrence (BCR) and to determine the detection rate of ⁶⁸Ga-PSMA PET/CT dependent of prostate-specific antigen (PSA) levels. Materials and methods: In total, 189 PCa patients scanned with ⁶⁸Ga-PSMA PET/CT for detection of BCR after curatively intended treatment with either radical prostatectomy (n = 153) or radiotherapy (n = 36) were included. Clinicopathological information at the time of diagnosis (PSA, clinical tumor-stage, International Society of Urological Pathology Grade Group and whether ⁶⁸Ga-PSMA PET/CT was used for primary staging), treatment (RT/RP and histopathology of the prostatectomies), and pre-PET PSA were collected from medical records. Results: Of the 189 ⁶⁸Ga-PSMA PET/CT scans, 103 (54.5%) were positive for BCR of PCa. No significant coherency was observed between detection rate and any clinicopathological variables at diagnosis. Detection rates significantly increased with rising PSA: <0.5 ng/mL = 28%, 0.5 ≤ 1 ng/mL = 39%, 1 ≤ 2 ng/mL = 64%, 2 ≤ 5 ng/mL = 87.5% and ≥5 ng/mL = 97%. Conclusions: The detection rate of PCa recurrence was strongly dependent of pre-PET PSA levels. None of the additional clinical variables acquired during primary staging, prostatectomy pathology reports, nor primary staging imaging modality affected the detection rate.

Original language	English
Article number	195
Journal	Diagnostics
Volume	12
Issue	1
Number of pages	11
DOIs	https://doi.org/10.3390/diagnostics12010195
Publication status	Published - Jan 2022

Keywords

Biochemical recurrence
Detection rate
Ga-PSMA
Ga-Prostate-Specific Membrane Antigen PET/CT
Predictors
Prostate cancer

Access to Document

10.3390/diagnostics12010195Licence: CC BY

Check availability with the Royal Danish Library

Cite this

@article{28bcb063222f46c994438821ed3725ae,

title = "Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET/CT",

abstract = "Objectives: To explore the existence of new predictors of the 68Ga-Prostate-Specific Membrane Antigen (PSMA) PET/CT detection rate at biochemical recurrence (BCR) and to determine the detection rate of 68Ga-PSMA PET/CT dependent of prostate-specific antigen (PSA) levels. Materials and methods: In total, 189 PCa patients scanned with 68Ga-PSMA PET/CT for detection of BCR after curatively intended treatment with either radical prostatectomy (n = 153) or radiotherapy (n = 36) were included. Clinicopathological information at the time of diagnosis (PSA, clinical tumor-stage, International Society of Urological Pathology Grade Group and whether 68Ga-PSMA PET/CT was used for primary staging), treatment (RT/RP and histopathology of the prostatectomies), and pre-PET PSA were collected from medical records. Results: Of the 189 68Ga-PSMA PET/CT scans, 103 (54.5%) were positive for BCR of PCa. No significant coherency was observed between detection rate and any clinicopathological variables at diagnosis. Detection rates significantly increased with rising PSA: <0.5 ng/mL = 28%, 0.5 ≤ 1 ng/mL = 39%, 1 ≤ 2 ng/mL = 64%, 2 ≤ 5 ng/mL = 87.5% and ≥5 ng/mL = 97%. Conclusions: The detection rate of PCa recurrence was strongly dependent of pre-PET PSA levels. None of the additional clinical variables acquired during primary staging, prostatectomy pathology reports, nor primary staging imaging modality affected the detection rate.",

keywords = "Biochemical recurrence, Detection rate, Ga-PSMA, Ga-Prostate-Specific Membrane Antigen PET/CT, Predictors, Prostate cancer",

author = "{Tranberg Christensen}, Mads and Jochumsen, {Mads Ry{\o}} and S{\o}ren Klingenberg and S{\o}rensen, {Karina Dalsgaard} and Michael Borre and Kirsten Bouchelouche",

year = "2022",

month = jan,

doi = "10.3390/diagnostics12010195",

language = "English",

volume = "12",

journal = "Diagnostics",

publisher = "MDPI AG",

number = "1",

}

Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by ⁶⁸Ga-PSMA PET/CT. / Tranberg Christensen, Mads; Jochumsen, Mads Ryø ; Klingenberg, Søren et al.
In: Diagnostics, Vol. 12, No. 1, 195, 01.2022.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET/CT

AU - Tranberg Christensen, Mads

AU - Jochumsen, Mads Ryø

AU - Klingenberg, Søren

AU - Sørensen, Karina Dalsgaard

AU - Borre, Michael

AU - Bouchelouche, Kirsten

PY - 2022/1

Y1 - 2022/1

N2 - Objectives: To explore the existence of new predictors of the 68Ga-Prostate-Specific Membrane Antigen (PSMA) PET/CT detection rate at biochemical recurrence (BCR) and to determine the detection rate of 68Ga-PSMA PET/CT dependent of prostate-specific antigen (PSA) levels. Materials and methods: In total, 189 PCa patients scanned with 68Ga-PSMA PET/CT for detection of BCR after curatively intended treatment with either radical prostatectomy (n = 153) or radiotherapy (n = 36) were included. Clinicopathological information at the time of diagnosis (PSA, clinical tumor-stage, International Society of Urological Pathology Grade Group and whether 68Ga-PSMA PET/CT was used for primary staging), treatment (RT/RP and histopathology of the prostatectomies), and pre-PET PSA were collected from medical records. Results: Of the 189 68Ga-PSMA PET/CT scans, 103 (54.5%) were positive for BCR of PCa. No significant coherency was observed between detection rate and any clinicopathological variables at diagnosis. Detection rates significantly increased with rising PSA: <0.5 ng/mL = 28%, 0.5 ≤ 1 ng/mL = 39%, 1 ≤ 2 ng/mL = 64%, 2 ≤ 5 ng/mL = 87.5% and ≥5 ng/mL = 97%. Conclusions: The detection rate of PCa recurrence was strongly dependent of pre-PET PSA levels. None of the additional clinical variables acquired during primary staging, prostatectomy pathology reports, nor primary staging imaging modality affected the detection rate.

AB - Objectives: To explore the existence of new predictors of the 68Ga-Prostate-Specific Membrane Antigen (PSMA) PET/CT detection rate at biochemical recurrence (BCR) and to determine the detection rate of 68Ga-PSMA PET/CT dependent of prostate-specific antigen (PSA) levels. Materials and methods: In total, 189 PCa patients scanned with 68Ga-PSMA PET/CT for detection of BCR after curatively intended treatment with either radical prostatectomy (n = 153) or radiotherapy (n = 36) were included. Clinicopathological information at the time of diagnosis (PSA, clinical tumor-stage, International Society of Urological Pathology Grade Group and whether 68Ga-PSMA PET/CT was used for primary staging), treatment (RT/RP and histopathology of the prostatectomies), and pre-PET PSA were collected from medical records. Results: Of the 189 68Ga-PSMA PET/CT scans, 103 (54.5%) were positive for BCR of PCa. No significant coherency was observed between detection rate and any clinicopathological variables at diagnosis. Detection rates significantly increased with rising PSA: <0.5 ng/mL = 28%, 0.5 ≤ 1 ng/mL = 39%, 1 ≤ 2 ng/mL = 64%, 2 ≤ 5 ng/mL = 87.5% and ≥5 ng/mL = 97%. Conclusions: The detection rate of PCa recurrence was strongly dependent of pre-PET PSA levels. None of the additional clinical variables acquired during primary staging, prostatectomy pathology reports, nor primary staging imaging modality affected the detection rate.

KW - Biochemical recurrence

KW - Detection rate

KW - Ga-PSMA

KW - Ga-Prostate-Specific Membrane Antigen PET/CT

KW - Predictors

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85123104983&partnerID=8YFLogxK

U2 - 10.3390/diagnostics12010195

DO - 10.3390/diagnostics12010195

M3 - Journal article

C2 - 35054362

VL - 12

JO - Diagnostics

JF - Diagnostics

IS - 1

M1 - 195

ER -